In this engaging discussion, Michael Metzger, CEO of Syndax Pharmaceuticals and a veteran in biopharmaceuticals, shares insights into their groundbreaking dual drug launches. He elaborates on the strategic in-licensing model that fueled their success and the meticulous due diligence behind choosing the right assets. Metzger also talks about the innovative menin inhibitor Revyforge and CSF1R antibody NICTIMVO, emphasizing their potential in oncology and the importance of pediatric care. His approach to tactical launch operations and data-driven strategies offers a fresh perspective on biotech growth.
27:29
forum Ask episode
web_stories AI Snips
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
question_answer ANECDOTE
Unusual Leadership Journey
Michael Metzger described joining Syndax in 2015 and partnering with Briggs Morrison to refocus the company through licensing and development.
They swapped roles later, with Metzger becoming CEO and Morrison leading R&D, illustrating a close leadership partnership.
volunteer_activism ADVICE
How To In-License Winning Assets
Do exhaustive due diligence and leverage your network when in-licensing assets to find high-potential programs.
Negotiate nimbly and communicate commitment to inventors to win competitive deals and accelerate development.
insights INSIGHT
Prioritize Translatable Biology
Syndax targeted mechanisms where compelling preclinical biology would translate to clear clinical impact.
Early clinical validation energized the team and investors to continue investing in development.
Get the Snipd Podcast app to discover more snips from this episode
Synopsis:
Few biotechs can pull off what Syndax Pharmaceuticals has achieved — two first-in-class oncology drug launches, built entirely through strategic in-licensing and disciplined execution.
In this episode, host Alok Tayi sits down with Michael Metzger, Chief Executive Officer of Syndax, to explore how the company identified breakthrough assets, advanced them through development, and successfully commercialized them within a span of just a few years.
Metzger unpacks Syndax’s distinctive model — leveraging external innovation, rapid clinical validation, and precision in go-to-market strategy — to create measurable patient and shareholder value. From the first menin inhibitor approved in acute leukemia to a novel CSF1R antibody reshaping GVHD and fibrosis care, Syndax’s portfolio embodies science that scales.
The conversation offers an insider’s perspective on risk management, deal-making, data-driven decision-making, and why speed to market has become the new differentiator in biotech. A must-listen for investors, executives, and founders navigating the complexities of growth in a capital-intensive industry.
Biography:
Michael A. Metzger is a seasoned biopharmaceutical executive with extensive leadership experience in company building, operations, and strategic transactions across the life sciences industry. He currently serves as the Chief Executive Officer of Syndax Pharmaceuticals, a publicly traded oncology company, a role he assumed in 2022. Prior to this, Michael served as President and Chief Operating Officer of Syndax from 2015 and has been a member of the company’s Board of Directors since 2019.
Previously, Michael held leadership roles at Regado Biosciences, Inc, where he served as President and CEO and guided the company through a successful merger with Tobira Therapeutics. He also served as Executive Vice President and COO at Mersana Therapeutics, Inc., where he oversaw key strategic initiatives in ADC development for oncology. Earlier in his career, Michael held senior roles in business development and M&A at Forest Laboratories, LLC, contributing to its transformation ahead of its acquisition by Allergan plc. He also held leadership positions at Onconova Therapeutics, Inc., and was a Managing Director at MESA Partners, Inc., a healthcare-focused venture capital firm.
Michael has served on several public and private company boards, including CTI BioPharma Corp., acquired by SOBI AB in 2023, and continues to be active in guiding innovative biotech organizations.
Michael holds a B.A. from George Washington University and a M.B.A. in Finance from the NYU Stern School of Business.
Biotech 2050 Podcast